BMC Nephrology (Feb 2024)

Steroid-resistant minimal change nephrotic syndrome associated with thymoma treated effectively with rituximab following thymectomy and cyclosporine: a case report

  • Yusaku Watanabe,
  • Keiji Hirai,
  • Momoko Hirata,
  • Taisuke Kitano,
  • Kiyonori Ito,
  • Susumu Ookawara,
  • Hisashi Oshiro,
  • Yoshiyuki Morishita

DOI
https://doi.org/10.1186/s12882-024-03485-2
Journal volume & issue
Vol. 25, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background Minimal change nephrotic syndrome (MCNS) can be complicated by thymoma; however, no standard therapy for thymoma-associated MCNS has yet been established. We herein describe a case of steroid-resistant MCNS associated with thymoma, treated effectively with rituximab. Case presentation A 71-year-old Japanese man was referred to our department with severe proteinuria (20 g/gCr). Renal biopsy showed minimal change disease and computed tomography revealed an anterior mediastinal mass. Based on these findings, he was diagnosed with thymoma-associated MCNS. He was treated with oral prednisolone (50 mg/day) and cyclosporine, and underwent thymectomy and plasma exchange. However, no improvement in proteinuria was observed. He therefore received intravenous rituximab 500 mg, resulting in a marked decrease in proteinuria from 5328 to 336 mg/day after 1 week. Conclusions This case suggests that rituximab might be an effective therapy in patients with steroid-resistant MCNS associated with thymoma.

Keywords